Inhalation Sciences: Q3 2022, Stronger order intake but increased backlog - Redeye

Redeye comments on Inhalation Sciences’ Q3 2022 report. Q3 sales came in at SEK1.8m, 57% higher than the same period last year (SEK1.1m). However, we lower our sales expectations for 2022e, make minor changes from 2023e and increase our WACC. This results in a lower fair value range with a decreased base case from SEK23 to SEK20.

Länk till analysen i sin helhet: https://www.redeye.se/research/864913/inhalation-sciences-q3-2022-stronger-order-intake-but-increased-backlog?utm_source=finwire&utm_medium=RSS